Literature DB >> 18093519

Correction of fragile X syndrome in mice.

Gül Dölen1, Emily Osterweil, B S Shankaranarayana Rao, Gordon B Smith, Benjamin D Auerbach, Sumantra Chattarji, Mark F Bear.   

Abstract

Fragile X syndrome (FXS) is the most common form of heritable mental retardation and the leading identified cause of autism. FXS is caused by transcriptional silencing of the FMR1 gene that encodes the fragile X mental retardation protein (FMRP), but the pathogenesis of the disease is unknown. According to one proposal, many psychiatric and neurological symptoms of FXS result from unchecked activation of mGluR5, a metabotropic glutamate receptor. To test this idea we generated Fmr1 mutant mice with a 50% reduction in mGluR5 expression and studied a range of phenotypes with relevance to the human disorder. Our results demonstrate that mGluR5 contributes significantly to the pathogenesis of the disease, a finding that has significant therapeutic implications for fragile X and related developmental disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18093519      PMCID: PMC2199268          DOI: 10.1016/j.neuron.2007.12.001

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  37 in total

Review 1.  Local protein synthesis and spine morphogenesis: Fragile X syndrome and beyond.

Authors:  Aaron W Grossman; Georgina M Aldridge; Ivan Jeanne Weiler; William T Greenough
Journal:  J Neurosci       Date:  2006-07-05       Impact factor: 6.167

2.  Learning induces long-term potentiation in the hippocampus.

Authors:  Jonathan R Whitlock; Arnold J Heynen; Marshall G Shuler; Mark F Bear
Journal:  Science       Date:  2006-08-25       Impact factor: 47.728

3.  Metabotropic glutamate receptors trigger homosynaptic protein synthesis to prolong long-term potentiation.

Authors:  C R Raymond; V L Thompson; W P Tate; W C Abraham
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

4.  Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome.

Authors:  Ben Tucker; Robert I Richards; Michael Lardelli
Journal:  Hum Mol Genet       Date:  2006-10-25       Impact factor: 6.150

Review 5.  Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP.

Authors:  Paul M Lea; Alan I Faden
Journal:  CNS Drug Rev       Date:  2006

6.  Anisomycin infused into the hippocampus fails to block "reconsolidation" but impairs extinction: the role of re-exposure duration.

Authors:  Ann E Power; Daniel J Berlau; James L McGaugh; Oswald Steward
Journal:  Learn Mem       Date:  2006 Jan-Feb       Impact factor: 2.460

7.  Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression.

Authors:  Lingfei Hou; Marcia D Antion; Daoying Hu; Corinne M Spencer; Richard Paylor; Eric Klann
Journal:  Neuron       Date:  2006-08-17       Impact factor: 17.173

8.  (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features.

Authors:  A M Peier; K L McIlwain; A Kenneson; S T Warren; R Paylor; D L Nelson
Journal:  Hum Mol Genet       Date:  2000-05-01       Impact factor: 6.150

Review 9.  Fragile X: translation in action.

Authors:  Mark F Bear; Gül Dölen; Emily Osterweil; Naveen Nagarajan
Journal:  Neuropsychopharmacology       Date:  2007-10-17       Impact factor: 7.853

Review 10.  Fmr1 KO mice as a possible model of autistic features.

Authors:  Maude Bernardet; Wim E Crusio
Journal:  ScientificWorldJournal       Date:  2006-09-20
View more
  477 in total

1.  Social peers rescue autism-relevant sociability deficits in adolescent mice.

Authors:  Mu Yang; Kayla Perry; Michael D Weber; Adam M Katz; Jacqueline N Crawley
Journal:  Autism Res       Date:  2010-10-06       Impact factor: 5.216

2.  Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.

Authors:  Laura K K Pacey; Sujeenthar Tharmalingam; David R Hampson
Journal:  J Pharmacol Exp Ther       Date:  2011-06-02       Impact factor: 4.030

3.  Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome.

Authors:  Aparna Suvrathan; Charles A Hoeffer; Helen Wong; Eric Klann; Sumantra Chattarji
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

4.  Delayed stabilization of dendritic spines in fragile X mice.

Authors:  Alberto Cruz-Martín; Michelle Crespo; Carlos Portera-Cailliau
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

Review 5.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 6.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

Review 7.  Stem cells and modeling of autism spectrum disorders.

Authors:  Beatriz C G Freitas; Cleber A Trujillo; Cassiano Carromeu; Marianna Yusupova; Roberto H Herai; Alysson R Muotri
Journal:  Exp Neurol       Date:  2012-10-02       Impact factor: 5.330

Review 8.  FMR1: a gene with three faces.

Authors:  Ben A Oostra; Rob Willemsen
Journal:  Biochim Biophys Acta       Date:  2009-02-21

Review 9.  LTD-like molecular pathways in developmental synaptic pruning.

Authors:  Claire Piochon; Masanobu Kano; Christian Hansel
Journal:  Nat Neurosci       Date:  2016-09-27       Impact factor: 24.884

10.  Elevated ERK/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice.

Authors:  Kirsty Sawicka; Alexander Pyronneau; Miranda Chao; Michael V L Bennett; R Suzanne Zukin
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.